Project Grant R01HL175555
Award Date
9/15/24
Completion Date
6/30/28
Dollars Obligated
$1.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...
This federal Project Grant award of $683,564 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the contribution of aberrant alveolar epithelial cells to the development and progression of pulmonary fibrosis. The 5-year award to The Trustees of the University of Pennsylvania, which began on Jul 1, 2025, will investigate how stress signaling through the PERK-ISR pathway impacts the emergence and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $690,626 to the Regents of the University of Michigan to conduct research on the role of type I interferon signaling in modulating acute lung injury and regeneration of the alveolar epithelium. The key objectives are to: 1) identify the molecular effectors linking interferon signaling to cell cycle arrest in respiratory epithelial cells, 2)...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $277,610.00 to Duke University to research the role of TP53 regulation in alveolar epithelial transitional cell state and the contribution of this transitional cell state to pulmonary fibrosis. The project aims to uncover the molecular mechanisms regulating alveolar epithelial cell states and determine the impact of the transitional cell state on pulmonary fibrosis,...
This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under CFDA Program 93.837 - Cardiovascular Diseases Research to a research collaboration between Henry Ford Health and Michigan State University Health Sciences. The grant aims to screen novel compounds that can reverse profibrotic gene signatures associated with idiopathic pulmonary fibrosis (IPF), a fatal lung disease with limited treatment options. The project involves three key objectives: 1) in silico...